Download App

Log in to access Online Inquiry
Company Overview More
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company’s partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.
CEO: Higgins, John L.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

LGND Ligand Pharmaceuticals

89.875+3.145+3.63%
Trading Session 05/17 10:18 ET
High
89.875
Open
89.120
Turnover
459.18K
Low
88.465
Pre Close
86.730
Volume
5.15K
Market Cap
1.52B
P/E(TTM)
66.57
52wk High
169.980
Shares
16.86M
P/E(Static)
27.15
52wk Low
77.800
Float Cap
1.42B
Bid/Ask %
33.33%
Historical High
278.620
Shs Float
15.81M
Volume Ratio
0.25
Historical Low
6.600
Dividend TTM
--
Div Yield TTM
300
P/B
1.91
Dividend LFY
--
Div Yield LFY
333.80%
Turnover Ratio
0.03%
Amplitude
1.63%
Avg Price
89.160
Lot Size
1
Float Cap
1.42B
Bid/Ask %
33.33%
Historical High
278.620
Shs Float
15.81M
Volume Ratio
0.25
Historical Low
6.600
Dividend TTM
--
P/B
1.91
Dividend LFY
--
Turnover Ratio
0.03%
Amplitude
1.63%
Avg Price
89.160
Lot Size
1
Price Forecast

No Data

News

Comment